Evaluation of the effect of administering N-acetyl-glucosamine-containing green tea supplement on biomarkers for cartilage metabolism in healthy individuals without symptoms of arthritis: a randomized double-blind placebo-controlled clinical study

Authors

  • Akihito Tomonaga Tana Orthopedic Surgery
  • Mitsuhiko Fukagawa Kitashinyokohama Orthopedic Surgery
  • Hiroki Ikeda Satoen Food and Drug Laboratories, Satoen Co., Ltd.
  • Toshiyuki Hori Satoen Food and Drug Laboratories, Satoen Co., Ltd.
  • Masaharu Ohkawara Satoen Food and Drug Laboratories, Satoen Co., Ltd.
  • Isao Nagaoka Department of Host Defense and Biochemical Research Juntendo University Graduate School of Medicine

DOI:

https://doi.org/10.31989/ffhd.v6i12.309

Abstract

Background: To evaluate the chondroprotective action of an N-acetyl-glucosamine (GlcNAc)-containing supplement on the joint health of healthy individuals without symptoms of arthritis, we conducted a randomized double-blind placebo-controlled clinical trial. 

Methods: Subjects (n=100, 51.3 ± 1.0 years (mean ± SE)) without symptoms of arthritis were randomly assigned to receive a 1000 mg GlcNAc-containing diet (GlcNAc group) or a placebo diet (placebo group) once a day for 16 weeks, and the effect on the cartilage metabolism was evaluated by analyzing the ratio of type II collagen degradation to synthesis using type II collagen degradation (C2C) and synthesis (PIICP) markers.

Results: The results indicated that the changes in the C2C/PIICP ratios from the baseline were slightly suppressed in the GlcNAc group compared with those in the placebo group at weeks 16 during the intervention and 4 weeks after the intervention. However, there was no significant difference between the two groups. To make the effect of GlcNAc even more clear, the subjects with joint loading and impaired cartilage metabolism were evaluated. Interestingly, the changes in the C2C/PIICP ratios from the baseline were significantly suppressed in the GlcNAc group compared with the placebo group at weeks 16 during the intervention and 4 weeks after the intervention. Moreover, test supplement-related adverse events were not essentially observed during and after the intervention.

Conclusions: These observations suggest that the oral administration of GlcNAc at a dose of 1000 mg/day exerts a chondroprotective action on the healthy individuals by lowering the C2C/PIICP ratio, which indicates relative reduction of type II collagen degradation and increase of type II collagen synthesis, without apparent adverse effect. 

Key words: N-acetyl-glucosamine, biomarker, cartilage metabolism, joint health

Downloads

Published

2016-12-30

Issue

Vol. 6 No. 12 (2016): December 2016

Section

Research Articles

License

Authors retain the copyright of their articles and grant the Functional Food Center (FFC) and its journals the right of first publication under the terms of the Creative Commons Attribution 4.0 International License.

This license permits unrestricted use, distribution, and reproduction in any medium, including commercial use, provided the original author(s) and source are properly credited. Authors may post and share their published work freely, provided that the original publication in this journal is acknowledged.

By submitting to this journal, authors confirm that their manuscripts are original, not under consideration elsewhere, and that they hold the necessary rights to grant this license. The Functional Food Center encourages open scientific exchange and allows derivative and extended works, provided attribution to the original publication is maintained.